[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625515":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":40,"studyPopulation":40,"armGroups":47,"interventions":60,"overallOfficials":71,"centralContacts":81,"locations":89,"responsibleParty":136,"collaborators":138,"id":146,"slug":40,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":40,"eligibilityCriteria":151,"healthyVolunteers":147,"sex":152,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":40,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":167,"whyStopped":40,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},{"fullName":5,"class":6},"Helsinki University Central Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":40},[9],{"measure":10,"description":11,"timeFrame":12},"Time in Range","Percentage (%) of the time patients' glucose levels are within the target range based on continuous glucose monitoring (time in range =TIR, 3.9-10 mmol\u002Fl).","During the first 2 years",[14,17,21,25,28,31,34,37],{"measure":15,"description":16,"timeFrame":12},"TINR","Time spent (%) in normoglycemic range (TINR, 3.9-7.8 mmol\u002Fl) based on continuous glucose monitorin (CGM) data",{"measure":18,"description":19,"timeFrame":20},"Complications","The development of diabetes-related complications such as diabetic nephropathy, diabetic retinopathy, neuropathy, coronary artery disease","15 years",{"measure":22,"description":23,"timeFrame":24},"HbA1c","The change in HbA1c levels (mmol\u002Fmol) during the treatment between the groups","2 years",{"measure":26,"description":27,"timeFrame":24},"Mean sensor glucose value","The change in mean sensor glucose value (mmol\u002Fl) obtained from continuous glucose monitoring between the groups during treatment",{"measure":29,"description":30,"timeFrame":24},"Glycemic variability","The change in glycemic variability (coefficient of variation CV (SD\u002Fmean sensor glucose x 100%)) obtained from continuous glucose monitoring data between the groups during treatment",{"measure":32,"description":33,"timeFrame":12},"Continuous Ketone monitoring (CKM)","Continous Ketone monitoring with a CKM sensor will be performed at 2 time points during the follow-up period",{"measure":35,"description":36,"timeFrame":20},"Cost-effectiveness","The cost-effectiveness of different treatment modalities for T1D in children with Cost-Utility Analysis modeling",{"measure":38,"description":39,"timeFrame":12},"Custom food list","The Custom Food List is a personalized menu integrated into the AID pump. Patients can select a predefined meal from the list before eating, without calculating the carbohydrate content, and the pump automatically delivers the preset insulin dose assigned to that item. We evaluated the impact of using the Custom Food List on Time in range (TIR, %), Time in Normoglycemic Range (TINR, %), Time below Range (TBR, %), and postprandial glucose levels compared with conventional carbohydrate counting.",null,{"allocation":42,"interventionModel":43,"interventionModelDescription":40,"primaryPurpose":44,"observationalModel":40,"timePerspective":40,"maskingInfo":45},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":46,"maskingDescription":40,"whoMasked":40},"NONE",[48,54],{"label":49,"type":50,"description":51,"interventionNames":52},"Early AID-treatment","EXPERIMENTAL","Automated insulin delivery system (Omnipod 5) is initiated after T1D diagnosis. Omnipod5 uses a SmartAdjust™ closed-loop algorithm to automate insulin delivery. Algorithm continuously predicts glucose trends and self-adjusts insulin delivery within safety boundaries. Continious glucose monitoring (CGM) is used.",[53],"Device: Omnipod 5",{"label":55,"type":56,"description":57,"interventionNames":58},"Control group","ACTIVE_COMPARATOR","Multiple daily insulin injections (MDI) is initiated after T1D with a standard treatment protocol. Continious glucose monitoring (CGM) is used.",[59],"Drug: Multiple daily injections of insulin",[61,66],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":40},"DEVICE","Omnipod 5","Omnipod5 uses a SmartAdjust™ closed-loop algorithm to automate insulin delivery. Algorithm continuously predicts glucose trends and self-adjusts insulin delivery within safety boundaries",[49],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":40},"DRUG","Multiple daily injections of insulin","Multiple daily infections of insulin to treat type 1 diabetes",[55],[72,75,78],{"name":73,"affiliation":5,"role":74},"Anna-Kaisa Tuomaala, MD, PhD","STUDY_DIRECTOR",{"name":76,"affiliation":5,"role":77},"Tero Varimo, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":79,"affiliation":5,"role":80},"Mari-Anne Pulkkinen, MD, PhD","STUDY_CHAIR",[82,86],{"name":73,"role":83,"phone":84,"phoneExt":40,"email":85},"CONTACT","+358505430180","anna-kaisa.tuomaala@hus.fi",{"name":76,"role":83,"phone":87,"phoneExt":40,"email":88},"+358445573392","tero.varimo@hus.fi",[90,116],{"facility":91,"status":40,"city":92,"state":40,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":102},"Jorvi Hospital","Espoo","02740","Finland","FI",{"type":97,"coordinates":98},"Point",[99,100],24.6522,60.2052,{"lat":100,"lon":99},[103,104,108,109,111,112,114],{"name":73,"role":83,"phone":84,"phoneExt":40,"email":85},{"name":105,"role":83,"phone":106,"phoneExt":40,"email":107},"Mari-Anne Pulkkinen, MD,PhD","+358094711","mari-anne.pulkkinen@hus.fi",{"name":79,"role":77,"phone":40,"phoneExt":40,"email":40},{"name":73,"role":110,"phone":40,"phoneExt":40,"email":40},"SUB_INVESTIGATOR",{"name":76,"role":110,"phone":40,"phoneExt":40,"email":40},{"name":113,"role":110,"phone":40,"phoneExt":40,"email":40},"Panu Oksanen, MD, PhD",{"name":115,"role":110,"phone":40,"phoneExt":40,"email":40},"Heidi Falk, MD",{"facility":117,"status":40,"city":118,"state":40,"zip":119,"country":94,"countryCode":95,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"New Children's Hospital","Helsinki","00029",{"type":97,"coordinates":121},[122,123],24.93545,60.16952,{"lat":123,"lon":122},[126,127,128,130,132,133,135],{"name":73,"role":83,"phone":84,"phoneExt":40,"email":85},{"name":76,"role":83,"phone":87,"phoneExt":40,"email":88},{"name":129,"role":110,"phone":40,"phoneExt":40,"email":40},"Tero Varimo, MD,PhD",{"name":131,"role":77,"phone":40,"phoneExt":40,"email":40},"Anne-Kaisa Tuomaala, MD,PhD",{"name":79,"role":110,"phone":40,"phoneExt":40,"email":40},{"name":134,"role":110,"phone":40,"phoneExt":40,"email":40},"Panu Oksanen, MD",{"name":115,"role":110,"phone":40,"phoneExt":40,"email":40},{"type":77,"investigatorFullName":76,"investigatorTitle":137,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"MD, PhD, pediatric endocrinologist",[139,142,144],{"name":140,"class":141},"Insulet Corporation","INDUSTRY",{"name":143,"class":141},"Abbott Diabetes Care",{"name":145,"class":141},"NordicInfu Care AB","100625515",false,"NCT07423637","The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment","The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment - a Prospective, Randomized, Controlled Study on Pediatric Patients With Type 1 Diabetes","Inclusion Criteria:\n\n* Children and adolescents aged 7-15 years who are re-cently (within a month) diagnosed with type 1 diabetes at the Children's and Adolescents' Unit of HUH at the New Children's Hospital and Jorvi Hospital\n\nExclusion Criteria:\n\n* Addison's disease\n* Renal failure\n* Untreated coeliac disease\n* Untreated thyroid disorder\n* Poorly controlled asthma, per investigator judgment.\n* Unresolved adverse skin conditions in the area of sensor placement (e.g. pso-riasis, rash, Staphylococcus infection).\n* Participating in an investigational study (drug or device) wherein he\u002Fshe has received treatment from an investigational study drug or device in the last 2 weeks before enrollment into this study, as per investigator judgment.","ALL","7 Years","16 Years",{"count":156,"type":157},100,"ESTIMATED","INTERVENTIONAL",[160],"NA","The purpose of this study is to investigate the effect of early initiated automated insulin de-livery (AID) treatment in type diabetes in children aged 7-16 years to glycemic control, diabe-tes distress of patients and caregivers, long-term micro- and macrovascular complications and cost-effectiveness compared to multiple daily injections (MDI) and continuous glucose monitoring (CGM). The immediate costs of AID therapy are higher than costs of multiple daily injection therapy, and there has been debate whether the more expensive AID therapy is justified. No research on the cost-effectiveness of AID use in children has been conducted so far in Finland, and there is generally very little research data on the long-term treatment of type 1 diabetes with AID systems. AID therapy has been studied from the point of diagno-sis of type 1 diabetes in two centers (USA and the UK) but from the perspective of maintain-ing subject's own insulin secretion. A long-term randomized and controlled study on the out-comes and cost-effectiveness of AID therapy, started from diagnosis of diabetes, is essential to create evidence-based data for optimizing current treatment recommendations.\n\nOur hypothesis is that AID treatment keeps the glycemic outcomes in targets in the long term and decreases diabetes distress. During longer time, AID system decreases the amount of micro- and macrovascular complications and is cost-effective treatment for children with type 1 diabetes (CwT1D).",[163],"Type 1 Diabetes",[165,166],"type 1 diabetes","Automated insulin delivery system","NOT_YET_RECRUITING","2026-03-13",{"date":170,"type":171},"2026-03-17","ACTUAL",{"date":173,"type":157},"2026-04-01",{"date":175,"type":157},"2028-12-31",{"name":5,"class":6},2]